Switzerland-based Memo Therapeutics has discovered multiple SARS-CoV-2 neutralising antibodies with the potential for development as immunotherapy against Covid-19.
Since March, the company has selected certain donors from Covid-19 patients in the country. The selection criteria was for patients who had a clinical course of the disease indicative of a potent antibody response.
Memo Therapeutics collected blood samples from the selected donors and used its microfluidic DROPZYLLA discovery platform to find virus-neutralising antibodies.
The platform is designed to allow the production of complete recombinant human antibody repertoires. It is said to preserve all characteristics present in each patient’s B cells.